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Abstract. Estimating the effect of a treatment on a given outcome, conditioned
on a vector of covariates, is central in many applications. However, learning the
impact of a treatment on a continuous temporal response, when the covariates
suffer extensively from measurement error and even the timing of the treatments
is uncertain, has not been addressed. We introduce a novel data-driven method
that can estimate treatment-response trajectories in this challenging scenario. We
model personalized treatment-response curves as a combination of parametric
response functions, hierarchically sharing information across individuals, and a
sparse Gaussian process for the baseline trend. Importantly, our model considers
measurement error not only in treatment covariates, but also in treatment times, a
problem which arises in practice for example when treatment information is based
on self-reporting. In a challenging and timely problem of estimating the impact of
diet on continuous blood glucose measurements, our model leads to significant
improvements in estimation accuracy and prediction.
Keywords: Treatment-response trajectory · Bayesian methods · Errors-in-variables
· Hierarchical modeling · Gaussian process · Wearable self-monitoring devices
1 Introduction
Increasing popularity of electronic health records (EHRs) and smart healthcare services
has led to accumulation of large quantities of heterogeneous data, with potential to
considerably improve the efficiency of clinical practice and health services [34]. This
highlights the importance of novel machine learning techniques for EHR data, which can
be integrated with mobile apps to provide personalized guidance for purposes ranging
from early diagnosis to support for lifestyle change [12,27]. The latter is specifically
relevant to reduce the cost of chronic diseases in the face of the aging population. For
instance, the annual economic cost of diabetes in the U.S. is approximately $250 billion
[1].
Inferring relationships between correlated variables is essential in many fields. An
important question is to estimate a patient’s response to a given treatment, comparing
the patient’s data from before and after the treatment. A traditional solution is to use
randomized controlled trials, which, however may be infeasible due to the cost or ethical
considerations. One possibility is to use mechanistic models, specifically tailored for the
ar
X
iv
:1
90
6.
03
98
9v
1 
 [c
s.L
G]
  1
0 J
un
 20
19
2 G. Zhang et al.
problem, and use data to learn about their unknown parameters. However, these models
require substantial expert knowledge and are not applicable if the underlying mechanism
is unknown. On the other hand, data-driven methods, trained on observational EHR data,
provide a promising alternative.
Estimating the impact of a treatment is particularly challenging when the response
is a continuous curve consisting, for example, of a time-series of measurements of a
biological marker. In such cases, the outcome is typically modeled by a Gaussian process
[35], but also neural networks have been considered [21]. The treatment may either be a
continuous dose function [42], or a discrete event in time [45,41]. The latter approach
is often relevant in practice when treatments are recorded as discrete events, even if
their true duration is not exactly zero. Treatment data are usually sparse, and hence it
is essential to share relevant information in a probabilistic model. A latent trajectory
model of [39] uses additive components to explain variation on population and individual
levels. Conditional random fields can be incorporated to further capture correlations
between different treatment types [40], and multivariate response curves can be modeled
by learning latent structure [42] shared across the outcomes.
Despite increased recent attention, there are still crucial issues in treatment-response
estimation that have not been addressed when the response is continuous. Most im-
portantly, the treatments are consistently assumed to be exactly measured and known,
while in reality the treatment input may be severely perturbed by numerous factors.
This problem dramatically escalates for user-reported treatment data, which potentially
results in complete discredit of the findings [20]. The erroneous effect is two-fold, i.e.,
in addition to measurement error in covariates, the actual time of the treatment might
be known only approximately. Another issue arises from the competing relationship
between a counterfactual trend, i.e., the evolution of the outcome assuming no treatment,
and the treatment response. When modeled and trained jointly, it easily happens that
a flexible trend completely overrides the treatment response, and therefore these two
components are often trained separately in practice.
To address the mentioned shortcomings, we introduce errors-in-variables (EIV)
framework for modeling of continuous treatment-response trajectories. The EIV models
account for measurement errors not only in the output variable, as common regression,
but also in the inputs [13,14]. They are closely related to latent-variable models in
machine learning [28,4], and based on modeling the unobserved true values from which
noisy observations are obtained. Our contributions can be summarized as follows:
– We formulate an EIV model for personalized treatment-response trajectories, where
a treatment comprises a vector of noisy covariates and treatment times are uncertain.
– We introduce an interpretable hierarchical prior on the treatment effects that effi-
ciently shares information between individuals, and allows training the full model
jointly, appropriately balancing between the trend and the responses.
– In a challenging topic, representative of the current technological mega-trend on
self-monitoring data from wearable devices, we show our method can meaningfully
estimate the personalized impact of diet on continuous blood glucose measurements.
The code and data used in the analyses are available at [link added upon acceptance,
reviewers can view the material in Supplement] and allow fully reproducing our results.
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2 Related work
Treatment response: Besides machine learning, the problem of treatment response
estimation has been studied in various fields, including informatics for medicine and
social sciences, where the data-driven approach can bring advantages compared to the
experimental trials [30]. For example, individual-level treatment response prediction
has been studied for schizophrenia [5] and depression [33]. An empirical comparison
of classifiers for treatment-response prediction for chemoradiotherapy appears in [9].
Topics studied in social sciences include the effect of a discrete treatment, years of
education, on an individuals’ income [6], and allowing a response to depend on social
interactions and treatments for other individuals [24].
Mechanistic models: In contrast to the data-driven approaches used in machine
learning, mechanistic models use substantial knowledge of a specific problem to charac-
terize the system with differential equations, and inference is done for example using
filtering algorithms. Similar to our application, [3] and [2] study blood glucose dynamics,
affected by nutrition and other factors. Another example is a computational model of
the physiological mechanisms for type-2 diabetes, aiming to quantify factors useful for
prevention of the disease [37].
EIV models for treatment response: In contrast to the vast body of research con-
cerning data-driven methods for the prediction of a treatment response, very little is
known about their performance when measurement error is present. Authors of [46]
study a method for inferring causal directions using EIV models, but they do not focus on
the response conditioned on specific treatments. Regression on various student covariates,
incorporating EIV, has been used to predict standardized test scores [22]. In [26], the
effect of measurement error on a binary treatment response is analyzed, underlining the
devastating impact of ignoring such errors. A model for measurement errors has been
used to quantify uncertainty in order to increase the confidence in detecting genuine
treatment changes for liver metastases [31].
None of these works address the problem of estimating the impact of a multivariate
vector of covariates on a continuous response with measurement error in covariates and
uncertainty in treatment timing, the topic of this paper.
3 Methods
In this section, we first review EIV models on a general level. Then we describe three
essential components of our model for personalized treatment-response trajectories:
a hierarchical prior on parametric treatment-responses functions, a Gaussian process
model for the trend, and measurement error models. Throughout the section, we present
the model in generic terms, but also outline the specific model that we use in Section
4.2 to estimate the impact of diet, recorded as nutrient contents of different meals, on
continuous blood glucose measurements.
Our model is fully Bayesian, yielding uncertainty estimates for all parameters, es-
sential in scientific applications. Inference is done using Markov chain Monte Carlo
(MCMC) with the state-of-the-art No-U-Turn (NUTS) sampler [17] implemented in soft-
ware PyMC3 [36]. Implementation details are discussed below and in the supplementary,
and can be viewed in full in the published code.
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Fig. 1: a) General formulation of the EIV model. For clarity, parameters associated
with the distributions are not shown. (b) Model for personalized treatment-response
trajectories. Details of the model are discussed in the text.
3.1 Errors-in-variables models
EIV models, a.k.a. measurement error models, are regression or classification models
that, in contrast to most existing models, account for errors not only in the output variable
but also in inputs [7,38,15,10]. Though commonly neglected, input mismeasurement
may be extremely harmful. For example in simple linear regression it leads to biased
estimates that can not be corrected for even with an infinite sample, while, on the
other hand, unbiased homoscedastic error in the output variable only induces additional
variability [7]. A graphical model for a general EIV model is presented in Figure 1a,
where X∗ and Y∗ represent the true values of the inputs and the output, and X and Y are
the corresponding noisy observations. The most important type of mismeasurement is
classical error, which corresponds to independence of an error term from the true value.
Except for the simplest case of linear regression [29], EIV modeling almost always
requires auxiliary information or data to correct the mismeasurement bias in estimation.
For problems that have an analytical solution, the bias can be corrected by a multiplication
or addition of external terms [18], e.g., an estimated reliability ratio [7]. For nonlinear
models, auxiliary data, e.g., instrumental variables or repeated measurements, can be
exploited to help correct bias, e.g., by estimating the density function of the true variable
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using a deconvolution technique [38]. However, without additional data, Bayesian EIV
modeling is currently the most powerful and flexible approach, as it allows incorporating
additional information in the form of distributional assumptions [15]. In this work, we
adopt the Bayesian approach.
Mathematically, the measurement error mechanism is defined as the distribution of
the noisy observed input, X, given the true unobserved input, X∗. The joint distribution
of the model factorizes accordingly as:
P(X∗,Y∗, X,Y, Θ) = P(X|X∗, θM)P(Y |Y∗, θN)P(Y∗|X∗, θR)P(X∗|θE)P(Θ), (1)
where P(X|X∗, θM) and P(Y |Y∗, θN) are called error or measurement models, P(Y∗|X∗, θR)
is a response or outcome model, P(X∗|θE) is an exposure model, and Θ = (θM , θN , θR, θE)
are the corresponding parameters. Bayes theorem can be used to infer the unknown
parameters and unobserved true values of the variables.
P(X∗,Y∗, Θ|X,Y) ∝ P(Θ)
N∏
i
P(Xi|X∗i , θM)P(Yi|Y∗i , θN)P(Y∗i |X∗i , θR)P(X∗i , θE). (2)
If the exposure model is noninformative and the measurement model is symmetric, i.e.,
P(Xi|X∗i , θM) = P(X∗i |Xi, θM), then the Bayesian modeling of classical error is equivalent
to another class of mismeasurement techniques know as Berkson error modeling [7].
P(X∗,Y∗, Θ|X,Y) ∝ P(Θ)
N∏
i
P(X∗i |Xi, θM)P(Yi|Y∗i , θN)P(Y∗i |X∗i , θR).
A well-known difficulty with EIV models is that they are often nonidentifiable [15],
i.e. there are more than one set of values for the unknowns leading to the same model.
This can be understood intuitively by noticing that the model stays the same if we
multiply the linear regression coefficients by a constant factor and at the same time
divide the estimated true values of inputs by the same factor. Therefore, to achieve
identifiability, some crucial information about measurement model has to be assumed
or estimated, e.g., the variance of a classical additive error in simple linear regression
[7]. The Bayesian paradigm offers a unique solution to the nonidentifiability of the EIV
models, as long as mismeasurement is modest and the prior is sufficiently good [16].
3.2 Model for treatment-response trajectories
Notation: A graph of our model for treatment-response trajectories is presented in Figure
1b. We assume there are N patients, and a trajectory consisting of a time series of length
Gn of the outcome (e.g. blood glucose) is observed for each individual:
yn = (yn1, . . . , ynGn )
T , n = 1, . . . ,N.
These measurements have been taken at times
τn = (τn1, . . . , τnGn )
T , n = 1, . . . ,N.
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Furthermore, each patient has Mn observed treatments (e.g. meals eaten), indexed by
m ∈ 1, . . . ,Mn, where each treatment is characterized by P covariates:
xnm = (xnm1, . . . , xnmP)T , for all m, n,
and the corresponding recorded treatment times are
tn = (tn1, . . . , tnMn )
T , for all n.
Here, xnm and tnm are assumed to be noisy observations of the treatment covariates and
timings, and their true unobserved values are denoted by x∗nm and t∗nm, respectively.
Outcome model: We model the observed outcome trajectory of individual n, yn, as
yn = Tn +
∑
m
Rnm + e,
where Tn ∈ RGn is a counterfactual trend (i.e. it describes the evolution of the outcome
had the treatment not been taken), Rnm ∈ RGn is the additive response to the mth
treatment, and e = (e1, . . . , eGn)T is the vector of errors with ei ∼ N(0, σ2y). We note
that the sum of the trend and the responses can be viewed as a trajectory for a ’clean’
outcome (omitted from Figure 1b), of which a version yn corrupted by Gaussian noise is
observed. Additive response functions can be seen as a continuous extension of scalar
average treatment effect (ATE) which is defined as the expected difference of outcomes
before and after treatment.
Response function: Response functions specify how treatments affect the outcome
over time, and they should be specified to suit the application at hand, balancing flexibil-
ity, interpretability, etc. For example, if interpretability is not needed and the amount of
data is large, non-parametric functions that learn the shape of the response are attractive.
On the other hand, parametric functions are suitable when data are scarce, and they are
often interpretable, which is valuable in itself but also helps specifying prior knowledge
to improve accuracy. In the application of learning the impact of meals on blood glucose
(Section 4.2), we model the treatment response using a bell-shaped parametric function
Rnm := f (∆nm, hnm, lnm) := hnm exp
{−0.5(∆nm − 3lnm)2
l2nm
}
, (3)
where a lag vector ∆nm = τn − t∗nm represents the time since a specific treatment. The
shape of this response is shown in Figure 2a and it is determined by two parameters
hnm and lnm with straightforward interpretations: hnm is the height of the response, and
lnm is the length-scale which is proportional to the ’width’ or ’duration’ of the response.
The main challenge in our application is scarceness and noisiness of data, with only 13
individuals and on average 10 meals per patient. We also tried a more flexible three-
parameter response used in [41], which allows a skewed response (see Figure 2a), but this
model suffered from convergence problems, for which reason we selected the simpler
alternative.
In applications it is often of interest to measure how the response depends on
treatment covariates, and therefore we allow these parameters to depend on the covariates:
hnm = (βhn)
Tx∗nm, and
lnm = (βln)
Tx∗nm, for all n,m.
(4)
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In Equation (4), the coefficient vectors βhn, β
l
n ∈ RP represent the personalized impact of
each of the P covariates on the height or width of the response for the nth individual.
To share information across individuals, we introduce a Bayesian hierarchical prior, see
[11], and assume that the personalized height and length-scale coefficients, βhn and β
l
n,
are drawn from common distributions:
βhn ∼ NP(β˜h, Σh) and βln ∼ NP(β˜l, Σl).
A hyperprior is further placed on the mean parameters of these distributions:
β˜h ∼ NP(0, Σ˜h) and β˜l ∼ NP(0, Σ˜l)
The hierarchical prior introduces shrinkage and facilitates estimation of the personalized
coefficients with limited data. Further details are given in the Supplementary material.
Counterfactual trend: A counterfactual trend represents the outcome assuming no
treatment has been taken. It has to be sufficiently flexible to handle any variation in the
outcome that is not accounted for by the treatments. In this paper, we model the trend
Tn(t) for individual n using a Gaussian Process (GP) [35]:
Tn(t) ∼ GP(0, k(t, t′|θTn )),
where θTn are parameters associated with the kernel function k(x, x′|θTn). GPs are non-
parametric regression models with well-known closed-form formulas for posterior esti-
mation, which they inherit from the Normal distribution by assuming all training and
test data follow a joint Normal distribution. For example, if
Sn = yn −
∑
m
Rnm
is the residual of the outcome after subtracting the impact of the treatment responses,
then
Tn(t)|Sn ∼ N(µ∗, Σ∗), where
µ∗ = k(τn, t)TK(τn, τn)−1Sn, and
Σ∗ = k(t, t) − k(τn, t)TK(τn, τn)−1k(τn, t).
We refer the reader to [35] for more details about GPs. As the kernel, we use the sum of
Squared Exponential (SE) and constant kernels, where the former equips the GP with
desired smoothness, and the latter enables meaningful extrapolation to regions where
no input points have been observed. To speed up computation, we use a sparse GP
[35] instead of a full GP, which samples a small set of inducing points uniformly from
τn to achieve a low-rank approximation of K(τn, τn) and its inverse. A detailed prior
specification is provided in the Supplementary material.
Measurement models: Measurement models describe error in observations. With
self-reported data both covariates and the timing of a treatment may be uncertain. To
account for the uncertainty in treatment timing, we assume:
tnm ∼ N(t∗nm + dn, (σtn)2), for all n,m.
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In words, the observed time tnm is obtained from the true time t∗nm by shifting it with a
bias term dn, and adding Gaussian noise. The bias term dn represents reporting habits of
different individuals. For example, in the blood glucose application in Section 4.2, some
individuals may systematically report their meal after eating, while others may do this
before eating.
Different models are possible for treatment covariates, depending on the assump-
tions and data available [15]. Here we assume a simple perturbation on the amount of
treatment:
xnm = x∗nmδnm, where
δnm ∼ LogNormal(0, σ2x), for all n,m.
(5)
The coefficient δnm represents the error in the mth treatment of the nth individual. Intuition
in the blood glucose application is that users are able to report correctly what they have
eaten, but not how much. While the model (5) captures our understanding of the type of
mismeasurement expected in our data, more complicated models could also be justified,
but they would require stronger additional assumptions to resolve the nonidentifiability
of the EIV models. The model in (5) is identifiable and can be trained with relatively
little data, as we demonstate in Section 4.
Estimating t∗nm is straightforward as it only shifts the response, but does not change
its shape. However, estimating x∗nm is more complicated, and requires assuming that
the counterfactual trend is sufficiently regularized. Otherwise the trend could easily
compensate for the perturbation. We solve this by encouraging a large length-scale for
the squared exponential kernel in the prior. Further details, e.g., prior distributions for
x∗nm, t∗nm, and dn, are provided in the Supplementary material.
3.3 A note on causality
We briefly review results related to estimation of causal effects from observational data
on treatment-response trajectories [32,25,41], to enable a user of our method to judge to
what extent the effects found may or may not be interpreted causally. The causal effect
of an action A (e.g. a treatment) on Y is defined as P(Y = y|do(A = a)), where the do(·)
operator represents a manipulation of A to value a. The key assumption is that there are
no unmeasured confounders (NUC), such as Z2 in Figure 2b. Without Z2, the causal
effect of A on Y can be estimated from observational data using the adjustment formula:
P(Y = y|do(A = a)) =
∑
z1
P(Y = y|A = a,Z1 = z1)P(Z1 = z1).
Time-varying treatments (Figure 2c) further face an issue of treatment-confounder
feedback [25], which means that hidden confounders do not have to affect A directly to
create a spurious correlation between an action and future observations. A generalized
adjustment formula, g-formula, can still be used to calculate P(Y¯≥t |do(At−1, At)), see [8].
A useful result, applicable with our model, is to use the model to estimate P(Y¯≥t |A¯≤t, Y¯<t)
from observational data. Then, assuming NUC, the following holds [25]:
P(Y¯≥t |do(At), A¯<t, Y¯<t) = P(Y¯≥t |A¯≤t, Y¯<t). (6)
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Fig. 2: a) Two Response functions. The blue one is used in this paper, while the orange
one is used in [41], (b) Graphical model for a cross-sectional case, showing action
(A), response (Y), and observed and hidden confounders (Z1 and Z2), and (c) over-time
response with a single treatment, where confounders Z can be either observed or hidden.
In words, conditionally on the history of treatments and the outcome (and relevant
observed confounders not shown in the formula), the causal impact of the most recent
treatment on future outcomes can be estimated from observational data. This short-term
effect can be used, e.g., to select between alternative treatments available at a certain
point in time, when the relevant history of the individual is known.
In Section 4.2 we analyse the impact of diet on blood glucose. Based on domain
knowledge, we know that diet is a prominent cause of changes in blood glucose. Fur-
thermore, in our data we often see a rapid increase and decrease in blood glucose after a
meal. Therefore, it seems plausible that meals affect blood glucose causally. However,
in general, the causal assumptions can not be verified from observational data, and it
is possible that some confounder affects both glucose and diet, but the effect of any
such confounder is expected to be small compared to the impact of diet. Hence, while
interpreting our results causally seems reasonable, we can not make assertions of this.
More generally, with emergence of modern wearable self-monitoring devices, it will
be possible to measure all relevant factors that could affect blood glucose much more
comprehensively, and the NUC assumption is reasonable. Our model is straightforward
to extend to such data.
4 Experiments
In this section, we first examine identifiability and accuracy of our model using simulated
data, and then use it to analyze a real-world dataset comprising diet and continuous
blood glucose measurements. Throughout, we compare four models, in an increasing
order of complexity (later models include the previous as special cases):
– Mind : Separate models for individuals.
– Mhier : Model with the hierarchical prior for the responses to share information
across individuals.
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– Mhier+time : Time uncertainty included.
– Mhier+time+cov : Uncertainty in covariates included.
4.1 Identifiability and accuracy of the models on simulated datasets
As a simple experiment, we first study the identifiability of the EIV model when there
is measurement error in the covariates. We simulate artificial data using a toy model
specified as the sum of a linear trend and the parametric treatment response from
Equation (3). The dimension of treatment covariates is here set to 2, and each input
is perturbed with an additive term drawn from N(1, 0.22). We analyze the data using
the EIV model that assumes measurement error, and a model that disregards the noise
in the covariates. Results and further details for this simple setup are presented in the
Supplementary material, and they show that the EIV model recovers all true inputs and
effect sizes with high accuracy, while the model that neglects the noise leads to biased
coefficient estimates with wide confidence intervals.
To study the accuracy and identifiability of our method in a more realistic simulated
setup, we first fit our model to the real-world data from Subsection 4.2, and use the fitted
model to simulate responses and trends for two individuals. We perturb half of the inputs
according to Equation (5) and let the model use the perturbed inputs and try to recover
the true inputs and parameters. The performance of all models depends on the relative
contributions of the trend and responses, and we scale up the response with a factor of 5,
which facilitates a meaningful comparison.
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Fig. 3: Simulation results. Left: true and estimated perturbations for one individual (the
other one shown in Supplement); Center: true and estimated coefficients for the height of
the response for 5 covariates; Right: Cosine similarity of concatenated height coefficient
vectors from all individuals against the true value with different levels of perturbation
(higher value is better). Two different prior SDs, 0.1 and 0.2, were considered for model
Mhier+time+cov.
Results for one individual are shown in Figure 3, and for the other in the Supple-
mentary material. We see that the direction of each non-zero perturbation is estimated
correctly (left panel), and this is true also for the other individual (Supplementary). On
the other hand, if there is no perturbation, the model may even then estimate non-zero
perturbations, introducing additional noise. This reflects the trade-off between flexibility
and overfitting, and highlights the importance of carefully validating the model to suit the
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amount and complexity of data. We also see that the regression coefficients are estimated
accurately by the EIV model (center), and that the benefit from using EIV becomes more
significant when the size of the perturbation increases (right). However, a too loose EIV
prior (large SD) may actually harm the performance by introducing additional noise,
when the true perturbation is small.
4.2 Experiments on real-world glucose data
The data contain blood glucose measurements and dietary records. These anonymized
data were provided by the Obesity Research Unit at the University of Helsinki, Fin-
land, and they are available for 13 non-diabetic individuals across three days. Diabetic
individuals were excluded because their metabolism differs extensively from healthy
individuals, and detailed modeling of that is beyond the scope of this work. The real-
valued blood glucose measurements were collected by a portable continuous glucose
monitoring system approximately every fifteen minutes. The dietary records consist of
user-reported contents and times of all meals eaten during the 3-day study period. Each
meal has been processed into amounts of five nutrients: starch, sugar, fiber, fat, and
protein. The goal of the analysis is to learn how these nutrients influence blood glucose.
Both the exact amounts of food eaten and the exact meal times are uncertain, as they are
based on values estimated and reported by users, which motivates the use of EIV models
for these data. A visualization of the data (and results) for one individual is shown in
Figure 4, and for all other individuals in the Supplement. Some markers may be missing
due to device errors or when a user has removed the device.
Fig. 4: Visualization of the 3-day time series for one patient. Red and brown dots
represent glucose markers in the training and test sets, respectively. Meals are indicated
by vertical bars, colored according to amounts of different nutrients in the meal. The
green curve is the final fitted trajectory, and it is a combination of the dashed blue line, a
counterfactual trend, and the mean of red lines, which are posterior samples of treatment
responses. Horizontal arrows associated with the meals show the estimated difference
between true and observed meal times.
Metrics: The models are trained using data from the first two days, and the third day
is used for testing. The performance of treatment-response estimation is quantified using
five metrics Mi, i ∈ {1, . . . , 5}. M1 is the proportion of variance explained by the trend:
M1 =
1
N
∑
n
Var(Tn)
Var(yn)
.
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M2 indicates how much more is explained when also the treatment responses are in-
cluded:
M2 =
1
N
∑
n
Var(Tn + ∑mRnm)
Var(yn)
−M1.
In detail, a large M1 means that the outcome is mostly explained by the trend, and a small
M2 represents an inactive treatment response. These metrics are computed in regions of
non-zero treatment response. Metrics M3 and M4 are simply the mean squared errors in
the training and test data. They are calculated for all individuals for whom M2 indicates
that the response has been properly learned. Thus one patient, shown in Figure 5, with
M2 ≈ 0.05 for the baseline model Mhier is excluded from MSE calculations (other
patients have M2 > 0.3).
Because M4 measures pointwise error, it may be misleadingly low when the response
shape is correct if its location is inaccurate. Metric M5 is insensitive to the inaccuracy of
location, and it measures the absolute error in variance between predicted response and
outcome:
M5 =
1
N
∑
n
|Var
(∑
m
Rnm
)
− Var(yn)|
Because our interest is in estimation of the treatment response, and not the trend, we
calculate M4 and M5 in windows from one hour before to three hours after each meal.
We use the Mann–Whitney U-test [23] to test if other models are better than Mhier
in terms of test error M4. The reason for using Mhier as the baseline is the main
argument of this article that EIV modeling is beneficial when estimating treatment-
response trajectories, and Mhier is otherwise the same as Mhier+time and Mhier+time+cov
except that it the does not include the EIV components. We also compare the models
using an information criterion for predictive accuracy. The state-of-the-art criterion is
leave-one-out cross-validation (LOO) [43], which is used here.
M1
PVE
Trend
M2
PVE
Resp
M3
MSE
Train
M4
MSE
Test
M5
∆Var
Test
p-value
U-test
LOO pLOO SE
LOO
Mind 0.361 0.342 0.149 1.695 0.927 1.00 3549.64 246.64 318.8
Mhier 0.359 0.339 0.159 0.752 0.391 - 3587.87 214.62 317.28
Mhier+time 0.350 0.424 0.098 0.738 0.377 3.24e-4 2869.91 342.24 265.09
Mhier+time+cov 0.344 0.428 0.098 0.743 0.366 4.66e-3 2994.98 465.47 333.7
Table 1: Comparison of models using the real-world glucose data. The metrics M1
through M5 are defined in text, where PVE means Proportion of Variance Explained.
p-value tests if other models are better than Mhier in terms of M4. LOO stands for
leave-one-out cross-validation, pLOO is the estimated effective number of parameters,
and SE-LOO records the standard error in the LOO computations.
Results: Result are shown in Table 1. We see that all models outperform the non-
hierarchical baseline Mind by a large margin. Furthermore, taking treatment time in-
accuracy into account in Mhier+time improves significantly over the non-EIV model
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Mhier. In fact, estimation of the response fails completely for some individuals without
time EIV; the results with and without time uncertainty modeling for one such case are
shown in Figure 5. On the other hand, taking uncertainty in covariates into account does
not notably improve accuracy, which is likely caused by a combination of increased
flexibility and limited amount of data. Overall, models with EIV component outperform
the model without EIV in all metrics.
Fig. 5: Demonstration of time uncertainty modeling for one individual. Upper: Results
using Mhier+time, where arrows indicate the estimated difference between the true and
observed meal times; Bottom: Results using Mhier.
Interpretability of personalized treatment response is also of great interest; for
instance, understanding how an individual’s glucose level changes if she eats one more
unit of sugar. The overall goal of glucose monitoring is to keep the glucose level in
a given range, and both the amount of excess and the duration of the hyperglycemic
state are clinically important. Hence, a sensible parameter to consider is the impact of
different nutrients on the area of the response curve. Though this is not a parameter
of our model, it is straightforward to derive the personalized increase in response area
due to one unit increase of a specific nutrient ∆Anp (n ∈ 1, . . . ,N, p ∈ {1...P}), using
coefficients for height and width, which are modeled explicitly (see Supplement).
Overall, starch and sugar have the strongest positive impact on glucose (Figure
6a), consistent with the understanding that carbohydrates increase blood glucose [44].
Protein, on the other hand, has a negative impact, which has been observed before and
might represent a complex short-term interaction between nutrients [19]. An advantage
of our model is that we get personalized coefficients for each individual, as shown for
starch in Figure 6b, and for the other nutrients in the Supplement. Finally, posterior
uncertainty of personalized starch coefficients is shown in Figure 6c. Importantly, models
with EIV have much narrower confidence intervals, meaning that they are estimated
more accurately, thanks to increased flexibility that allows fitting the complex data.
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STARCH 9.57 4.29
SUGAR 6.36 4.97
FIBC 2.83 4.95
FAT 5.29 5.49
PROT −10.13 3.90
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Fig. 6: a). Average impact on response area ∆Anp by different nutrients; b) Histogram
of personalized starch coefficients and their mean (+/- one SD) (red); c) Posterior
uncertainty in the personalized starch coefficients.
5 Conclusion
We presented a hierarchical model with EIV components to estimate personalized
treatment-response trajectories when the covariates and timing of a treatment are impre-
cise. Our model demonstrates superior performance in both simulated and real-world
data on various metrics, and allows extracting interpretable and meaningful estimates
of the personalized impacts of treatment covariates, valuable in applications. Future
directions include extensions and identifiability of EIV modelling, and extending the
model to include interactions between covariates and other unmeasured confounders,
such as physical activity, for causal completeness.
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